Literature DB >> 15669879

Second-generation antihistamines: actions and efficacy in the management of allergic disorders.

Larry K Golightly1, Leon S Greos.   

Abstract

Antihistamines are useful medications for the treatment of a variety of allergic disorders. Second-generation antihistamines avidly and selectively bind to peripheral histamine H1 receptors and, consequently, provide gratifying relief of histamine-mediated symptoms in a majority of atopic patients. This tight receptor specificity additionally leads to few effects on other neuronal or hormonal systems, with the result that adverse effects associated with these medications, with the exception of noticeable sedation in about 10% of cetirizine-treated patients, resemble those of placebo overall. Similarly, serious adverse drug reactions and interactions are uncommon with these medicines. Therapeutic interchange to one of the available second-generation antihistamines is a reasonable approach to limiting an institutional formulary, and adoption of such a policy has proven capable of creating substantial cost savings. Differences in overall efficacy and safety between available second-generation antihistamines, when administered in equivalent dosages, are not large. However, among the antihistamines presently available, fexofenadine may offer the best overall balance of effectiveness and safety, and this agent is an appropriate selection for initial or switch therapy for most patients with mild or moderate allergic symptoms. Cetirizine is the most potent antihistamine available and has been subjected to more clinical study than any other. This agent is appropriate for patients proven unresponsive to other antihistamines and for those with the most severe symptoms who might benefit from antihistamine treatment of the highest potency that can be dose-titrated up to maximal intensity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15669879     DOI: 10.2165/00003495-200565030-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  525 in total

1.  Burn wound itch control using H1 and H2 antagonists.

Authors:  R A Baker; R A Zeller; R L Klein; R J Thornton; J H Shuber; R E Marshall; A G Leibfarth; J A Latko
Journal:  J Burn Care Rehabil       Date:  2001 Jul-Aug

2.  FDA approves OTC Claritin.

Authors: 
Journal:  FDA Consum       Date:  2003 Jan-Feb

3.  Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects.

Authors:  F W Fraunfelder; F T Fraunfelder
Journal:  Ophthalmology       Date:  2004-07       Impact factor: 12.079

4.  Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire.

Authors:  E F Juniper; A K Thompson; P J Ferrie; J N Roberts
Journal:  J Allergy Clin Immunol       Date:  1999-08       Impact factor: 10.793

Review 5.  Molecular events in allergic inflammation: experimental models and possible modulation.

Authors:  G W Canonica; G Ciprandi; G Passalacqua; G Pesce; A Scordamaglia; M Bagnasco
Journal:  Allergy       Date:  1997       Impact factor: 13.146

Review 6.  Clinical pharmacology of new histamine H1 receptor antagonists.

Authors:  F E Simons; K J Simons
Journal:  Clin Pharmacokinet       Date:  1999-05       Impact factor: 6.447

7.  Eosinophil infiltration: effects of H1 antihistamines.

Authors:  R Fadel; B David; R Rassemont; N Herpin-Richard; A Borgnon; J P Rihoux
Journal:  J Am Acad Dermatol       Date:  1991-06       Impact factor: 11.527

8.  Cetirizine treatment of allergic cough in children with pollen allergy.

Authors:  G Ciprandi; M Tosca; V Ricca; G Passalacqua; L Fregonese; L Fasce; G W Canonica
Journal:  Allergy       Date:  1997-07       Impact factor: 13.146

9.  A single-center, randomized, double-blind, placebo-controlled, crossover investigation of the effects of fexofenadine hydrochloride 180 mg alone and with alcohol, with hydroxyzine hydrochloride 50 mg as a positive internal control, on aspects of cognitive and psychomotor function related to driving a car.

Authors:  Fran Ridout; Ziba Shamsi; Robert Meadows; Sigurd Johnson; Ian Hindmarch
Journal:  Clin Ther       Date:  2003-05       Impact factor: 3.393

10.  Effect of cetirizine on cutaneous reactions to PAF, kallikrein and serum in patients with chronic urticaria.

Authors:  L Juhlin; J P Rihoux
Journal:  Acta Derm Venereol       Date:  1990       Impact factor: 4.437

View more
  14 in total

Review 1.  Drug-induced urinary retention: incidence, management and prevention.

Authors:  Katia M C Verhamme; Miriam C J M Sturkenboom; Bruno H Ch Stricker; Ruud Bosch
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

2.  Determination of Some Non-sedating Antihistamines via Their Native Fluorescence and Derivation of Some Quantitative Fluorescence Intensity - Structure Relationships.

Authors:  Michael E El-Kommos; Samia M El-Gizawy; Noha N Atia; Noha M Hosny
Journal:  J Fluoresc       Date:  2015-10-06       Impact factor: 2.217

Review 3.  Selecting the optimal oral antihistamine for patients with allergic rhinitis.

Authors:  Jeffrey M Lehman; Michael S Blaiss
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  Variability of histamine pharmacodynamic response in children with allergic rhinitis.

Authors:  Bridgette L Jones; Gregory Kearns; Kathleen A Neville; Catherine M T Sherwin; Michael M G Spigarelli; J Steven Leeder
Journal:  J Clin Pharmacol       Date:  2013-05-16       Impact factor: 3.126

Review 5.  Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.

Authors:  Philippe Devillier; Nicolas Roche; Christophe Faisy
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

6.  Improvement of effect of water-in-oil microemulsion as an oral delivery system for fexofenadine: in vitro and in vivo studies.

Authors:  E Gundogdu; I Gonzalez Alvarez; E Karasulu
Journal:  Int J Nanomedicine       Date:  2011-08-12

7.  H1 antihistamines: current status and future directions.

Authors:  F Estelle R Simons; Keith J Simons
Journal:  World Allergy Organ J       Date:  2008-09       Impact factor: 4.084

Review 8.  Respiratory allergies: a general overview of remedies, delivery systems, and the need to progress.

Authors:  Giuliano Molinari; Giselda Colombo; Cinzia Celenza
Journal:  ISRN Allergy       Date:  2014-03-12

9.  Efficacy and safety of using a warming needle for persistent allergic rhinitis: study protocol for a randomized controlled trial.

Authors:  Yuxiu Sun; Hong Zhao; Yongming Ye; Wenbin Nie; Wenjing Bai; Jia Liu; Sinuo Li; Fang Wang; Mingjuan Han; Liyun He
Journal:  Trials       Date:  2016-06-30       Impact factor: 2.279

10.  Combining MucilAir™ and Vitrocell® Powder Chamber for the In Vitro Evaluation of Nasal Ointments in the Context of Aerosolized Pollen.

Authors:  Julia Metz; Katharina Knoth; Henrik Groß; Claus-Michael Lehr; Carolin Stäbler; Udo Bock; Marius Hittinger
Journal:  Pharmaceutics       Date:  2018-05-10       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.